Synthace
ProfileJobs

Synthace

Suggest Edit
    • Healthbiotech
    The UK’s first dedicated synthetic biology company with a world leading platform of technologies for the rapid engineering and optimisation of novel biological production systems. A spin out of University College London, Synthace is already producing high-value research and development products for the pharmaceutical, agrochemical and fine chemicals industry. Synthace bioengineering is enabled by a tight integration of computational modelling and big data analysis with wet lab experimental design and validation, and novel molecular biology tools. While Synthace bioengineering is broadly applicable across multiple industry sectors, the company is focused towards applications in the production of specialty chemicals.
    Revenue(FY, 2013)
    £581
    Total Funding
    $16.2 M
    Type
    Private
    HQ
    London, GB
    Founded
    2011
    Size (employees)
    38 (est)+9%
    Website
    synthace.com
    Synthace was founded in 2011 and is headquartered in London, GB
    Report incorrect company information

    Key People/Management at Synthace

    Tim Fell

    Tim Fell

    CEO
    Christopher Grant Ward

    Christopher Grant Ward

    Co-Founder
    Markus Gershater

    Markus Gershater

    CSO
    Sean Ward

    Sean Ward

    Founder and CTO

    Synthace Office Locations

    Synthace has an office in London
    London, GB (HQ)
    2 Royal College St
    Show all (1)
    Report incorrect company information

    Synthace Financials and Metrics

    Summary Metrics

    Founding Date

    		2011

    Total Funding

    		$16.2 m

    Latest funding size

    		$9.90 m

    Time since last funding

    		7 months ago

    Investors

    		Rainbow Seed Fund, Amadeus Capital Partners, SOSV, Sami Mikati, Keith Willey, White Cloud Capital, Sharaf Yamani, John Anthony Knight, Eleven Two Capital, Sofinnova Partners, Bioeconomy Capital, David Lucas, Michail Eleftheriou
    Synthace's latest funding round in September 2017 was reported to be $9.9 m. In total, Synthace has raised $16.2 m

    Synthace Financials

    Synthace's revenue was reported to be £581 in FY, 2013
    GBP

    Revenue (FY, 2013)

    		581

    Net income (FY, 2013)

    		(361.6 k)

    EBITDA (FY, 2013)

    		(356.8 k)

    EBIT (FY, 2013)

    		(361.6 k)

    Cash (31-May-2017)

    		224.3 k
    GBPFY, 2012FY, 2013

    Revenue

    		581

    Operating expense total

    		362.2 k

    EBITDA

    		(356.8 k)

    EBITDA margin, %

    		(61413%)
    show all
    GBPFY, 2012FY, 2013

    Net Income

    		(43.1 k)(361.6 k)
    show all
    GBPY, 2017

    Financial Leverage

    		-1.6 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Luminist
    Health - Private
    Magenta Therapeutics
    Health - Private
    Glycomine
    Health - Private
    Cofactor Genomics
    Health - Private
    Compare competitors

    Synthace News and Updates

    September 19, 2017

    Synthace reels in $9.6 mln Series A

    London-based Synthace, the developer of the Antha operating system for biology, has raised $9.6 million in Series A funding. The investors included White Cloud Capital, Amadeus Capital Partners, Eleven Two Capital, Sofinnova Partners, SOSV and Bioeconomy Capital.
    Report incorrect company information
    Download PDF